Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts
Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts
View: Text | PDF
Research Article Oncology

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis

  • Text
  • PDF
Abstract

Osteosarcoma (OS), a malignant tumor of bone, kills through aggressive metastatic spread almost exclusively to the lung. Mechanisms driving this tropism for lung tissue remain unknown, though likely invoke specific interactions between tumor cells and other cells within the lung metastatic niche. Aberrant overexpression of ΔNp63 in OS cells directly drives production of IL-6 and CXCL8. All these factors were expressed at higher levels in OS lung metastases than in matched primary tumors from the same patients. Expression in cell lines correlated strongly with lung colonization efficiency in murine xenograft models. Lentivirus-mediated expression endowed poorly metastatic OS cells with increased metastatic capacity. Disruption of IL-6 and CXCL8 signaling using genetic or pharmaceutical inhibitors had minimal effects on tumor cell proliferation in vitro or in vivo, but combination treatment inhibited metastasis across multiple models of metastatic OS. Strong interactions occurred between OS cells and both primary bronchial epithelial cells and bronchial smooth muscle cells that drove feed-forward amplification of IL-6 and CXCL8 production. These results identify IL-6 and CXCL8 as primary mediators of OS lung tropism and suggest pleiotropic, redundant mechanisms by which they might effect metastasis. Combination therapy studies demonstrate proof of concept for targeting these tumor-lung interactions to affect metastatic disease.

Authors

Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts

×

Figure 4

Combined therapy with anti–IL-6 and anti-CXCL8 treatment reduces metastatic lung colonization in many xenograft models of metastatic osteosarcoma (OS), but does not affect growth of primary orthotopic tumors.

Options: View larger image (or click on image) Download as PowerPoint
Combined therapy with anti–IL-6 and anti-CXCL8 treatment reduces metasta...
(A) Validation of concept in multiple murine models of OS. To validate, studies were repeated in multiple OS models of metastasis including human OS xenografts (OS-17, 143B), canine OS xenografts (OSCA8 and OSCA16), and syngeneic/immunocompetent murine OS allografts (K7M2, F420). Subsequent to inoculation of OS cells, mice received either vehicle treatment or treatment with both sc144 and DF2156A for a period of 42 days. At the time that one mouse in either group met endpoint criteria, all mice within that study were euthanized and lungs harvested, metastases (Mets) counted. Representative lung sections shown (n = 5 to 15 mice per group as shown). (B) The effect of cytokine inhibitors on proliferation in vitro was evaluated using an Incucyte ZOOM live cell imaging system. Graphs represent number of cells per microscopic field in each culture condition, normalized to the average cell number in the vehicle control. (C) Mice bearing intratibial OS-17 tumors were treated with either vehicle or the combination of sc144 and DF2156A according to the same schedule used in the metastatic models. Tumor volume was calculated biweekly throughout treatment. All P values shown relative to control condition (vehicle). *P < 0.05; **P < 0.01; ***P < 0.001 by Mann-Whitney U test (A) or 1-way ANOVA with Tukey’s post hoc test (B and C).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts